Qualification of impurities based on metabolite data
Lars Weidolf(AstraZeneca (Sweden)), Bruce A. Trela(AbbVie (United States)), Jenny Ottosson(AstraZeneca (Netherlands)), Nenad Manevski(Roche (Switzerland)), Andrew Teasdale(AstraZeneca (United Kingdom)), Ron Ogilvie(Pfizer (United States)), Pascale Jacques(UCB Pharma (Belgium)), James Harvey(GlaxoSmithKline (United Kingdom)), Raphael Nudelman(Teva Pharmaceuticals (Israel)), Andreas Brink(Roche (Switzerland)), Joel P. Bercu(Eli Lilly (United States)), Martin A. Hayes(AstraZeneca (Japan)), Thomas Andersson(Knowledge Foundation), Susanne Glowienke(Novartis (Switzerland)), Chuang Lu(Sanofi (France)), Wolfgang Muster(Roche (Switzerland))
Cited by 20
Related Papers
OxyR
|Cell|2002|474
S-nitrosylation: spectrum and specificity
|Nature Cell Biology|2001|243
Drug Insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis
|Nature Clinical Practice Rheumatology|2008|197
An Integrated in Silico 3D Model-Driven Discovery of a Novel, Potent, and Selective Amidosulfonamide 5-HT<sub>1A</sub> Agonist (PRX-00023) for the Treatment of Anxiety and Depression
|Journal of Medicinal Chemistry|2006|141
A nitric oxide processing defect of red blood cells created by hypoxia: Deficiency of S-nitrosohemoglobin in pulmonary hypertension
|Proceedings of the National Academy of Sciences|2005|132